Beth Tréhu

Beth Tréhu

Company: Jounce Therapeutics

Job title: Chief Medical Officer


Elizabeth (Beth) G. Tréhu, M.D, FACP, is Chief Medical Officer of Jounce Therapeutics, a clinical stage immuno-oncology company dedicated to transforming the treatment of cancer by matching the right immunotherapy to the right patient. Dr. Tréhu designed and conducted her first cancer immunotherapy clinical trials in the early 1990s as an assistant professor and translational researcher at Tufts University School of Medicine, where her research focused on reducing the toxicity of high dose interleukin-2.  She has held oncology leadership positions in drug development from IND through post-marketing at Millennium Pharmaceuticals, Genzyme Corporation, Infinity Pharmaceuticals, and Promedior, Inc. and joined Jounce in 2015 to build and lead the clinical organization.  Dr. Trehu is a member of the Board of Directors of Constellation Pharmaceuticals. 

Dr. Tréhu was recognized as a ‘2012 Woman to Watch’ by Mass High Tech. She holds an M.D. from New York University School of Medicine and an A.B. cum laude from Princeton University 


Identification of a Predictive Biomarker for an Immune Agonist; Lessons Learned from Vopratelimab 10:45 am

• Translation of preclinical predictive biomarker data into the clinic is challenging for immunotherapies • A drug specific, treatment emergent, pharmacodynamic biomarker that was associated with clinical outcomes was critical to finding a predictive biomarker • A predictive biomarker optimized for prediction of the drug-specific pharmacodynamic biomarker was associated with improved clinical outcomes and is…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.